Mabwell (Shanghai) Bioscience Valuation

Q: What is the Fair Price of 688062 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

688062 (CN¥22.38) is trading below our estimate of [[fair value]] (CN¥110.23)

Is 688062 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 688062 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 688062 (CN¥22.38) is trading below our estimate of fair value (CN¥110.23)

Significantly Below Fair Value: 688062 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 688062?

Key metric: As 688062 barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for 688062. This is calculated by dividing 688062's market cap by their current book value.
What is 688062's PB Ratio?
PB Ratio	4.7x
Book	CN¥1.92b
Market Cap	CN¥8.94b

688062 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	56.2x
Enterprise Value/EBITDA	-9.4x
PEG Ratio	n/a

Price to Book Ratio vs Peers

How does 688062's PB Ratio compare to its peers?

The above table shows the PB ratio for 688062 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PB	Estimated Growth	Market Cap
Peer Average	5.5x
688382 InventisBio	3.2x	58.4%	CN¥5.6b
688373 Shanghai MicuRx Pharmaceutical	5.8x	25.6%	CN¥3.3b
688276 Changchun BCHT Biotechnology	2.5x	40.7%	CN¥10.7b
688656 HOB Biotech GroupLtd	10.6x	n/a	CN¥8.5b
688062 Mabwell (Shanghai) Bioscience	4.7x	58.2%	CN¥8.9b

Price-To-Book vs Peers: 688062 is good value based on its Price-To-Book Ratio (4.7x) compared to the peer average (5.5x).

Price to Book Ratio vs Industry

How does 688062's PB Ratio compare vs other companies in the CN Biotechs Industry?

0 Companies	Price / Book	Estimated Growth	Market Cap

No more companies available in this PB range

0 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Book vs Industry: 688062 is expensive based on its Price-To-Book Ratio (4.7x) compared to the CN Biotechs industry average (2.3x).

Price to Book Ratio vs Fair Ratio

What is 688062's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

688062 PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio	4.7x
Fair PB Ratio	n/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate 688062's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

China Resources Double-Crane PharmaceuticalLtd

CN¥21.4b

China Resources Double-Crane Pharmaceutical Co.,Ltd.

600062

CN¥20.80

-3.9%

12.1%

Dong-E-E-JiaoLtd

CN¥36.4b

Research and development, production, and sale of Ejiao and a series of Chinese patent medicines, health foods, and foods.

423

CN¥56.60

-3.0%

13.2%

Jiangsu Kanion PharmaceuticalLtd

CN¥8.1b

Researches and develops, produces, and sells Chinese medicines.

600557

CN¥14.29

-4.2%

-23.6%